HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Structured programs for the management of patients with non-alcoholic fatty liver disease in the work of a general practitioner

DOI: https://doi.org/10.29296/25877305-2022-05-02

Professor V. Skvortsov, MD; M. Ustinova
Volgograd State Medical University, Ministry of Health of Russia

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver diseases that affect >25% of the world’ population. NAFLD is associated with substantial morbidity and mortality of liver cirrhosis, hepatocellular carcinoma, diabetes mellitus, and cardiovascular diseases, which leads to a significant healthcare burden and a decrease in quality of life in a patient. According to international guidelines, lifestyle modification for weight loss remains the first-line intervention in patients with NAFLD. The article summarizes evidence-based recommendations for lifestyle changes and clinical management of patients with NAFLD.

non-alcoholic fatty liver disease
liver cirrhosis
diabetes mellitus
body mass index
cardiovascular diseases
lifestyle modification
weight loss
physical activity/exercises

  1. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64 (6): 1388–402. DOI: 10.1016/j.jhep.2015.11.004
  2. Seliverstov P.V., Radchenko V.G. A role of mitochondrial cytopathy during steatosis in patients with non-alcoholic fatty liver disease. Effektivnaya farmakoterapiya. 2017; 16: 16–24 (in Russ.).
  3. Seliverstov P.V. Ozhirenie kak faktor riska razvitiya serdechno-sosudistykh oslozhnenii na fone nealkogol’noi zhirovoi bolezni pecheni. Meditsinskii al’manakh. 2016; 1 (41): 61–3 (in Russ.).
  4. Seliverstov P.V., Dzhadkhav S.N., Tsurtsumia D.B. et al. Diagnostic capabilities in non-alcoholic fatty liver disease. RMJ. 2019; 5: 36–40 (in Russ.).
  5. Lazebnik L.B., Golovanova E.V., Turkina S.V. et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021; 1 (1): 4–52 (in Russ.). DOI: 10.31146/1682-8658-ecg-185-1-4-52
  6. Abenavoli L., Greco M., Milic N.et al. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients. 2017; 9 (8): 870. DOI: 10.3390/nu9080870
  7. Torres M.C.P., Bodini G., Furnari M. et al. Nuts and NonAlcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? Nutrients. 2020; 12: 3363. DOI: 10.3390/nu12113363
  8. Byrne C.D., Targher G. NAFLD: a multisystem disease. J Hepatol. 2015; 62 (1 Suppl): S47–64. DOI: 10.1016/j.jhep.2014.12.012
  9. Yaskolka Meir A., Rinott E., Tsaban G. et al. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut. 2021; 70 (11): 2085–95. DOI: 10.1136/gutjnl-2020-323106
  10. Cabo R., Mattson M.P. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. 2019; 381 (26): 2541–51. DOI: 10.1056/NEJMra1905136
  11. Klempel M.C., Kroeger C.M., Bhutani S. et al. Intermittent fasting combined with calorie restriction is effective for weight loss and cardio-protection in obese women. Nutr J. 2021; 11: 98. DOI: 10.1186/1475-2891-11-98
  12. Holmer M., Lindqvist C., Petersson S. et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial. JHEP Rep. 2021; 3 (3): 100256. DOI: 10.1016/j.jhepr.2021.100256
  13. Shim S.G., Jun D.W., Kim E.K. et al. Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model. J Gastroenterol Hepatol. 2013; 28 (12): 1877–84. DOI: 10.1111/jgh.12317
  14. Dunn W., Sanyal A.J., Brunt E.M. et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol. 2012; 57 (2): 384–91. DOI: 10.1016/j.jhep.2012.03.024
  15. Pezeshki A., Safi S., Feizi A. et al. The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease. Int J Prev Med. 2016; 7: 28. DOI: 10.4103/2008-7802.173051
  16. Münzel T., Sørensen M., Gori T. et al. Environmental stressors and cardio-metabolic disease: part I, II. Eur Heart J. 2017; 38 (8): 550–64. DOI: 10.1093/eurheartj/ehw269
  17. Kang D., Zhao D., Ryu S. et al. Perceived stress and non-alcoholic fatty liver disease in apparently healthy men and women. Sci Rep. 2020; 10: 38. DOI: 10.1038/s41598-019-57036-z
  18. Keating S.E., George J., Johnson N.A. The benefits of exercise for patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015; 9 :1247–50. DOI: 10.1586/17474124.2015.1075392
  19. Oh S., Shida T., Yamagishi K. et al. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study. Hepatology. 2015; 61: 1205–15. DOI: 10.1002/hep.27544
  20. Soto-Angona Ó., Anmella G., Valdés-Florido M.J. et al. Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. BMC Med. 2020; 18: 261. DOI: 10.1186/s12916-020-01713-8
  21. Jung H.-S., Chang Y., Kwon M.-J. et al. Smoking and the risk of non-alcoholic fatty liver disease: a cohort study. Am J Gastroenterol. 2019; 114: 453–63. DOI: 10.1038/s41395-018-0283-5
  22. Lazo M., Solga S.F., Horska A. et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010; 33 (10): 2156–63. DOI: 10.2337/dc10-0856
  23. George A.St., Bauman A., Johnston A. et al. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol. 2009; 24 (3): 399–407. DOI: 10.1111/j.1440-1746.2008.05694.x